The one-time-only dose to stop SMA progression
ZOLGENSMA® (onasemnogene abeparvovec-xioi) is a gene therapy for pediatric patients less than 2 years of age with spinal muscular atrophy (SMA)1
Complete Phase 3 SPR1NT data is available
The SPR1NT clinical trial is complete for presymptomatic patients with 2 and 3 copies of SMN2. View data for patients treated with ZOLGENSMA.
Getting started with ZOLGENSMA
Complete the ZOLGENSMA Prescription and Patient Consent Forms for eligible patients to help with insurance and prescription-related processes.
download
Follow Payne’s ZOLGENSMA journey
Payne’s SMA was first identified through newborn screening. His SMA diagnosis and 4 copies of SMN2 were later confirmed through genetic testing.
SEE PAYNE’S PROFILE
Patient support
The OneGene Program®, offered by Novartis Gene Therapies, is a comprehensive, individualized support program for families with pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) and their healthcare providers throughout the ZOLGENSMA treatment journey.
OneGene Program support includes:
- Answers to questions about ZOLGENSMA
- A dedicated, personalized support team focused on the needs of each family
- Verification of insurance benefits
- Coordination of financial assistance programs for eligible patients
Families can access the full range of OneGene Program support resources when the ZOLGENSMA Prescription Form and accompanying Patient Consent Form have been provided to the OneGene Program.
For questions call 1-855-441-GENE (4363),
Monday-Friday (8 AM to 8 PM ET)
Discover more about ZOLGENSMA
About ZOLGENSMA
Explore efficacy, safety, dosing, and how ZOLGENSMA works
Understand SMA
Learn about the signs and symptoms of SMA
Steps to treatment
What to know before, during, and after infusion day
Resources
Learn about resources available to your patients
Reference: 1. ZOLGENSMA [prescribing information]. Bannockburn, IL: Novartis Gene Therapies, Inc; 2023.